Pancreatic cancer, the molecular mechanisms that cause this cancer to develop has now been a recent breakthrough by two research teams, including one at the Maisonneuve-Rosemont (CIUSSS-EST, Montreal) and University of Montreal.
This biomedical research conducted jointly by the groups of Dr. Fredrick Antoine Mallette and Dr. Stephane Richard (McGill University / Lady Davis Institute for Medical Research) has shown that pancreatic tumors often lose the ability to express a small ribonucleic acid molecule called miR-137. This molecule induces a defence mechanism called cellular senescence, which keeps cancer cells in check. The loss of miR-137 works in conjunction with various mutations frequently observed in pancreatic tumours to trigger uncontrolled cell growth and then cancer.
"It is essential that we better understand the mechanisms that lead to the loss of miR-137 expression. Once we do, we can create therapeutic strategies to treat and prevent pancreatic cancer," said Dr. Fredrick Antoine Mallette.
A relentless cancer
In 2015, approximately 4800 people received a diagnosis of pancreatic cancer, and nearly 4600 Canadians succumbed to this terrifying disease. Although this cancer is the 12th highest in terms of incidence, it is 4th highest in cancer-related mortality. Survival rates for pancreatic cancer haven't improved in the past 40 years. This is why we urgently need to clarify the mechanisms of this cancer to find new therapeutic avenues that will change these grim statistics.